These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 12874825

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer.
    Chen TC, Schwartz GG, Burnstein KL, Lokeshwar BL, Holick MF.
    Clin Cancer Res; 2000 Mar; 6(3):901-8. PubMed ID: 10741714
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. 20-Cyclopropyl-cholecalciferol vitamin D3 analogs: a unique class of potent inhibitors of proliferation of human prostate, breast and myeloid leukemia cell lines.
    Koike M, Koshizuka K, Kawabata H, Yang R, Taub HE, Said J, Uskokovic M, Tsuruoka N, Koeffler HP.
    Anticancer Res; 1999 Mar; 19(3A):1689-97. PubMed ID: 10470102
    [Abstract] [Full Text] [Related]

  • 6. The anti-proliferative effects of 1alpha,25(OH)2D3 on breast and prostate cancer cells are associated with induction of BRCA1 gene expression.
    Campbell MJ, Gombart AF, Kwok SH, Park S, Koeffler HP.
    Oncogene; 2000 Oct 19; 19(44):5091-7. PubMed ID: 11042697
    [Abstract] [Full Text] [Related]

  • 7. Induction of apoptosis and inhibition of prostate and breast cancer growth by BGP-15, a new calcipotriene-derived vitamin D3 analog.
    Berkovich L, Ben-Shabat S, Sintov AC.
    Anticancer Drugs; 2010 Jul 19; 21(6):609-18. PubMed ID: 20335794
    [Abstract] [Full Text] [Related]

  • 8. 19-nor-26,27-bishomo-vitamin D3 analogs: a unique class of potent inhibitors of proliferation of prostate, breast, and hematopoietic cancer cells.
    Kubota T, Koshizuka K, Koike M, Uskokovic M, Miyoshi I, Koeffler HP.
    Cancer Res; 1998 Aug 01; 58(15):3370-5. PubMed ID: 9699668
    [Abstract] [Full Text] [Related]

  • 9. Altered SMRT levels disrupt vitamin D3 receptor signalling in prostate cancer cells.
    Khanim FL, Gommersall LM, Wood VH, Smith KL, Montalvo L, O'Neill LP, Xu Y, Peehl DM, Stewart PM, Turner BM, Campbell MJ.
    Oncogene; 2004 Sep 02; 23(40):6712-25. PubMed ID: 15300237
    [Abstract] [Full Text] [Related]

  • 10. Novel nonsecosteroidal vitamin D mimics exert VDR-modulating activities with less calcium mobilization than 1,25-dihydroxyvitamin D3.
    Boehm MF, Fitzgerald P, Zou A, Elgort MG, Bischoff ED, Mere L, Mais DE, Bissonnette RP, Heyman RA, Nadzan AM, Reichman M, Allegretto EA.
    Chem Biol; 1999 May 02; 6(5):265-75. PubMed ID: 10322128
    [Abstract] [Full Text] [Related]

  • 11. Vitamin D-induced up-regulation of tumour necrosis factor alpha (TNF-alpha) in prostate cancer cells.
    Golovko O, Nazarova N, Tuohimaa P.
    Life Sci; 2005 Jun 17; 77(5):562-77. PubMed ID: 15904673
    [Abstract] [Full Text] [Related]

  • 12. Growth inhibition and differentiation in human prostate carcinoma cells induced by the vitamin D analog 1alpha,24-dihydroxyvitamin D2.
    Bauer JA, Thompson TA, Church DR, Ariazi EA, Wilding G.
    Prostate; 2003 May 15; 55(3):159-67. PubMed ID: 12692781
    [Abstract] [Full Text] [Related]

  • 13. Selective growth-inhibitory, cell-cycle deregulatory and apoptotic response of apigenin in normal versus human prostate carcinoma cells.
    Gupta S, Afaq F, Mukhtar H.
    Biochem Biophys Res Commun; 2001 Oct 05; 287(4):914-20. PubMed ID: 11573952
    [Abstract] [Full Text] [Related]

  • 14. Autocrine TGFbeta signaling mediates vitamin D3 analog-induced growth inhibition in breast cells.
    Yang L, Yang J, Venkateswarlu S, Ko T, Brattain MG.
    J Cell Physiol; 2001 Sep 05; 188(3):383-93. PubMed ID: 11473365
    [Abstract] [Full Text] [Related]

  • 15. Growth inhibitory effects of 1alpha, 25-dihydroxyvitamin D(3) are mediated by increased levels of p21 in the prostatic carcinoma cell line ALVA-31.
    Moffatt KA, Johannes WU, Hedlund TE, Miller GJ.
    Cancer Res; 2001 Oct 01; 61(19):7122-9. PubMed ID: 11585744
    [Abstract] [Full Text] [Related]

  • 16. Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells.
    Peehl DM, Skowronski RJ, Leung GK, Wong ST, Stamey TA, Feldman D.
    Cancer Res; 1994 Feb 01; 54(3):805-10. PubMed ID: 7508338
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. 1Alpha,25dihydroxyvitamin D3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines.
    Moffatt KA, Johannes WU, Miller GJ.
    Clin Cancer Res; 1999 Mar 01; 5(3):695-703. PubMed ID: 10100724
    [Abstract] [Full Text] [Related]

  • 19. Mechanistic studies to evaluate the enhanced antiproliferation of human keratinocytes by 1alpha,25-dihydroxyvitamin D(3)-3-bromoacetate, a covalent modifier of vitamin D receptor, compared to 1alpha,25-dihydroxyvitamin D(3).
    Chen ML, Ray S, Swamy N, Holick MF, Ray R.
    Arch Biochem Biophys; 1999 Oct 01; 370(1):34-44. PubMed ID: 10496974
    [Abstract] [Full Text] [Related]

  • 20. Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3.
    Skowronski RJ, Peehl DM, Feldman D.
    Endocrinology; 1995 Jan 01; 136(1):20-6. PubMed ID: 7530193
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.